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Of all patients diagnosed with lung cancer, small cell lung cancer 
(SCLC) represents 13% of the cases in the Netherlands (Netherlands 
Comprehensive Cancer Organisation, 2019). SCLC is an aggressive 
tumour which is frequently metastasized at time of diagnosis, and 
therefore the majority of patients is diagnosed with extensive disease 
(ED; Carney, 2002; Lally, Urbanic, Blackstock, Miller, & Perry, 2007). 
The median survival for patients without systemic therapy has been 
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Abstract
Objective: Clinical outcome data on patients with extensive disease small cell lung 
cancer (ED SCLC) treated in routine practice is limited. The aim of this retrospective 
study is to present data on treatment patterns and survival in an unselected patient 
population with ED SCLC.
Methods: All	patients	diagnosed	with	ED	SCLC	between	2008	and	2014	in	six	Dutch	
large teaching hospitals (Santeon network) were included. We collected data on 




line	 treatment.	 For	 all	 treated	patients,	 the	mean	 age	was	66	 years.	 The	majority	
(72%) had a performance status (ECOG) of 0 or 1 at diagnosis. Median OS of treated 
patients	was	7.4	months.	Of	all	patients	with	first-line	treatment,	26%	received	<4	
cycles and dose reductions were observed in 29%.
Conclusion: After	first-line	systemic	treatment	in	ED	SCLC	the	fraction	of	patients	
receiving subsequent lines of treatment is rapidly decreasing. This information is nec-
essary as background for evaluation of the added value of future drugs under study 
for ED SCLC.
K E Y W O R D S
effectiveness, pharmacotherapy, real-world, small cell lung cancer, survival, treatment 
patterns
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reported to be 2 to 4 months (Carney, 2002; Meerbeeck, Fennell, & 
De Ruysscher, 2011).
Several studies have reported an improvement in survival after 
the	 introduction	 of	 chemotherapy	 in	 the	 1970s	 (Janssen-Heijnen	
et al., 2012). Despite numerous clinical trials, systemic treatment 
for patients with SCLC has not changed significantly in the past 
several decades (Byers & Rudin, 2015; Pietanza, Byers, Minna, & 
Rudin, 2015). The standard of care in Europe for newly diagnosed 
ED SCLC is a platinum-based chemotherapy with etoposide (Fruh 
et al., 2013). In case of chemotherapy-resistant disease a second-line 
treatment	 with	 topotecan	 can	 be	 started	 (Ardizzoni,	 2004;	 Fruh	
et al., 2013).
These treatment standards are based on clinical trial data, which 
often have excluded patients with a worse performance status, co-
morbidities and high age. Therefore, the question remains if patients 
with ED SCLC in daily practice show the same outcomes as those 
in clinical trials. The recent German TLK study showed that plati-
num-based combination chemotherapies accounted for 93% of all 
first-line treatments in patients with ED SCLC (Steffens et al., 2019). 
At	 least	50%	of	the	patients	received	a	second-line	treatment	and	
22% a third-line treatment. Regarding survival time, this study con-
cluded	 similarity	 with	 data	 from	 previously	 randomised	 trials.	 A	
limitation is that they started with patients receiving systemic treat-
ment thus not being able to report on the percentage of best sup-
portive care only after diagnosis.
A	recent	systematic	literature	review	on	real-world	effective-
ness of SCLC treatments by Povsic et al. also emphasized the 
limited number of treatment options in SCLC and lack of good 
quality real-world data about outcomes (Povsic et al., 2019). The 
aim of the present study is to provide good quality data on treat-
ment patterns, including best supportive care, and correspond-
ing survival times in an unselected patient population with ED 
SCLC.
2  | PATIENTS AND METHODS
2.1 | Data source and study participants
This study was performed within a network of seven large (non-
university) teaching hospitals in the Netherlands, named Santeon, 
which serves more than 12% of the Dutch patient population. We 
used the Santeon Care for Outcome (CfO) registry for identify-
ing	all	patients	diagnosed	with	ED	SCLC	between	2008	and	2014,	
and for collecting patient characteristics. Data on applied systemic 
pharmacotherapy for ED SCLC was derived from individual patient 
files. Furthermore, the Santeon Farmadatabase (SFD) was used for 
validation and collection of additional detailed data about systemic 
treatments. More details on the CfO registry and SFD can be found 
elsewhere	 (Cramer-van	 der	Welle	 et	 al.,	 2018;	Garde	 et	 al.,	 2019;	
Peters et al., 2017).
Study data were collected and managed using REDCap elec-
tronic	data	capture	tools	hosted	at	St.	Antonius	Hospital,	Utrecht/
Nieuwegein, the Netherlands (Harris et al., 2009). This study was 
approved by a medical research ethics committee (CMO registration 
number	2018-4338),	with	need	for	informed	consent	being	waived	
because of the retrospective nature of the study and anonymous 
handling of data.
2.2 | Patient characteristics and systemic treatment 
per patient
The following patient characteristics were collected from the CfO: 
date of diagnosis, age at diagnosis, gender, ECOG performance sta-
tus (PS), separate comorbidities (to calculate Charlson Comorbidity 
Index [CCI]) and date of death.
For every patient, all systemic treatments were extracted from 
both the individual patient files and the prescription data recorded in 
the SFD, including start and stop dates, number of cycles and dose, 
and whether it was first, second or further line of treatment. The initial 
systemic therapy following date of diagnosis was defined as first-line 
treatment. Switches from cisplatin to carboplatin due to toxicity were 
considered the same line. Second-line treatment was defined as sys-
temic treatment applied after completion or discontinuation because 
of disease progression of first-line treatment. Re-induction treatment 
(systemic treatment with the same or similar regimen as administered in 
the	previous	line,	≥90	days	after	finishing	first-line	treatment)	for	che-
mo-sensitive patients was considered a subsequent line of treatment.
2.3 | Real-world treatment outcomes
The overall survival (OS) for all treated patients was calculated using 
time between start date of systemic treatment and date of death. 
For patients receiving best supportive care, date of diagnosis was 
used	 to	calculate	OS.	Patients	 still	 alive	at	 January	31,	2018	 (date	
of update from Personal Records Database [BRP]) were given this 
end of follow-up date as imputed date of death (n = 7). Furthermore, 
progression-free survival (PFS) was calculated as time between start 
date of systemic treatment and date of progression when noted, or 




cycle less than planned for that regimen) and/or switches were as-
sessed within lines of treatment.
2.4 | Statistical analysis
Statistical Software (SPSS version 24 for Windows; IBM) was used 
for statistical analysis. In case of continuous data mean ± SD or me-
dian (range) was given, categorical data were analysed using chi-
square and continuous data using t	tests	and	one-way	ANOVA	when	
appropriate.
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3  | RESULTS
3.1 | Patient characteristics
We identified 792 patients diagnosed with ED SCLC in the period 
2008–2014,	 of	which	 568	 (72%)	 started	with	 first-line	 treatment.	
A	combination	therapy	with	cisplatin	or	carboplatin	and	etoposide	
is	the	most	applied	first-line	systemic	treatment	(96%	of	all	treated	
patients). Table 1 presents the baseline patient characteristics per 
systemic first-line treatment regimen, for all treated patients as a 
whole, and for patients who received best supportive care. For all 
treated	patients,	the	mean	age	at	diagnosis	was	66	years;	45%	were	
female.	The	majority	of	patients	(72%)	had	an	ECOG	PS	0–1	at	time	
of diagnosis and comorbidities were present in 57% of all patients 
(CCI	 >	 0).	 For	 all	 patients	 with	 best	 supportive	 care,	 87	 patients	
(39%)	had	an	ECOG	PS	0–1	at	 time	of	diagnosis,	but	nevertheless	
did not start first-line treatment for various reasons, for example, 
personal	preferences	or	very	rapid	progress	of	disease.	Table	A1	(ap-
pendix) presents the baseline characteristics for all treated patients 
on start of first, second or third-line treatment.
3.2 | Treatment patterns
Figure 1 shows the different treatment patterns of all patients to-
wards best supportive care (BSC). Of all patients treated with first-




patients (12%) received third-line treatment. In third-line, topotecan 
was most commonly applied (32%), followed by taxane-based regi-
mens	(31%).	Twelve	patients	(18%)	received	re-induction	treatment	
with a platinum-etoposide regimen. In fourth-line, topotecan was 




respectively. Median PFS and OS per line of systemic treatment 
were shown in Table 2. Median OS for patients with best supportive 
care (n = 224) was 0.9 months.
There was no difference in median OS for treated patients de-
pending on year of diagnosis (p	=	.868).	Furthermore,	no	significant	
difference was found in median OS for patients with second-line 
re-induction chemotherapy (platinum-etoposide) depending on time 
to	progression	from	end	date	of	first-line	therapy	(<6	months	[n = 54] 
vs.	≥6	months	 [n = 55]): median OS from start date of second-line 
therapy	was	5.6	and	7.0	months,	respectively	(p	=	.067).
Of all patients with first-line treatment, dose reductions were 
present	 in	 29%,	 early	 discontinuation	 in	 26%,	 and	 switches	 in	 8%	
of the patients (Table 3). Multivariate analysis showed a statistically 
significant association of age, ECOG PS and CCI with the occur-
rence of one or more proxies for toxicity (p	=	 .046,	 .004	and	.017,	
respectively).
4  | DISCUSSION
This study showed that after first-line systemic treatment in ED 
SCLC the fraction of patients receiving subsequent lines is rapidly 
decreasing. From 792 diagnosed patients, 72% started with first-line 
treatment. Of these patients, 41% received second-line treatment 
and only 12% third-line treatment. The median OS from start of first-
line treatment is 7.4 months. Combination therapy with platinum-
etoposide	is	the	most	applied	first-line	systemic	treatment	(96%	of	
all treated patients).
This is one of the few studies that provide a complete overview of 
treatment patterns and corresponding outcomes for an unselected 
population of patients with ED SCLC. To the best of our knowledge, 
the German TLK study of Steffens et al. (2019) and the cohort study 
of Tendler et al. (2020) are the only other recent studies including 










Patients, n 335 209 15 9 568 224
Age	at	diagnosis,	median	
(min–max)
68	(39–88) 64	(42–84) 68	(49–78) 61	(52–87) 66	(39–88) 74	(44–92)
Male, n (%) 203	(61) 93 (45) 13	(87) 2 (22) 311 (55) 129	(58)
Comorbidities	(CCI	≥	1),	n (%) 197 (59) 112 (54) 9	(60) 6	(67) 324 (57) 144	(64)
Missing 0 0 0 0 0 9 (4)
ECOG PS, n (%)
0–1 240 (72) 156	(75) 11 (73) 4 (44) 411 (72) 87	(39)
≥2 83	(25) 46	(22) 4 (27) 5	(56) 138	(24) 113 (50)
Missing 12 (4) 7 (3) 0 0 19 (3) 24 (11)
Abbreviations:	BSC,	best	supportive	care;	CCI,	Charlson	Comorbidity	Index;	CDE,	cyclophosphamide-doxorubicin-etoposide;	ECOG	PS,	Eastern	
Cooperative Oncology Group Performance Status.
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such data. Our findings are in line with Steffens et al. with regard 
to low percentages of patients receiving a second and third-line. 
Furthermore, we found a comparable percentage of platinum-based 
combination chemotherapy as first-line treatment. In addition to 
Steffens	et	al.,	our	study	revealed	that	28%	of	all	patients	diagnosed	
with ED SCLC received best supportive care only. This means that 
the statement of Steffens et al. that their results may not be gen-
eralised to the small group of patients not receiving any systemic 
treatment concerns more than a quarter of all patients diagnosed 
with ED SCLC (Steffens et al., 2019).
In contrast to the German TLK study, we found a lower me-
dian OS from first-line treatment (7.4 months, compared to 10.7 as 
found by Steffens et al.), whereas Tendler et al. reported a median 
OS of 7.0 months, which is in line with our findings. These differ-
ences may be related to differences in cohort selection. The TLK 
study included patients who received at least one palliative line of 
treatment, whereas in our study and in the study of Tendler et al. 
all patients who started first-line treatment were included (i.e. at 
least one cycle of treatment). The possibility exists that some pa-
tients have not made it into the Steffens et al. cohort because of 
early discontinuation of treatment due to rapid progression or tox-
icity. The remaining patients do have a better prognosis which is 
reflected in a longer median survival. Furthermore, it is not incon-
ceivable that the process of prospective enrolment of patients in 
the TLK study might have caused selection bias by missing patients 
with poor prognosis. For example, Steffens et al. reported 39% of 
all	 patients	with	 CCI	 ≥	 1	 and	 17%	with	 ECOG	PS	 ≥	 2,	 compared	
to 57% and 24% in our population treated with first-line systemic 
treatment.	 Another	 contrast	 with	 the	 German	 TLK	 Study	 is	 that	
in second-line regimens with paclitaxel or docetaxel were applied 
F I G U R E  1   Treatment patterns of ED SCLC patients. BSC, best supportive care; CDE, cyclophosphamide-doxorubicin-etoposide
 
1st line 










Median PFS (months) 5.8 3.4 3.4 3.7 4.7
Median OS (months) 7.4 4.6 3.7 5.1 6.0
Abbreviations:	OS,	overall	survival;	PFS,	progression-free	survival.
TA B L E  2   PFS and OS of treated 









Carboplatin-etoposide (n = 335) 26 27 2
Cisplatin-etoposide (n = 209) 35 23 18
CDE (n = 15) 40 33 7
Other (n = 9) 22 44 22
Overall 29 26 8
Abbreviation:	CDE,	cyclophosphamide-doxorubicin-etoposide.
TA B L E  3   Toxicity in patients with first-
line treatment
     |  5 of 6CRAMER-VAN DER WELLE Et AL.
more often in our population (19% vs. <3%). This is in contrast with 
the clinical practice guidelines in the US and Europe recommending 
topotecan for patients eligible for second-line treatment in case of 
chemotherapy-resistant	disease	(Ardizzoni,	2004;	Fruh	et	al.,;	Rudin	
et al., 2015). Topotecan is the only second-line drug approved by 
the	FDA	 (US	Food	 and	Drug	Administration).	One	 reason	 for	 this	
divergence from guidelines could be Netherlands based research of 
Groen et al. who observed a high response rate and mild toxicity of 
second-line carboplatin-paclitaxel in CDE-resistant SCLC patients 
(Groen et al., 1999).
A	strength	of	this	study	is	that	it	is	based	on	a	large	unselected	re-
al-world population of patients diagnosed with ED SCLC, geographi-
cally spread over the Netherlands. In addition, this study is based on 
high-resolution data with a very low number of missing values.
The limitations of this study primarily relate to the retrospec-
tive nature of the data collection and the time frame under study 
(2008–2014),	which	can	possibly	affect	the	generalisability	of	our	
findings to present daily clinical practice. On the other hand, we 
captured a time frame of >7 years without any effect of calendar 
year on the findings. Recently, improved OS and PFS were reported 
with	the	addition	of	atezolizumab	(Horn	et	al.,	2018)	or	durvalumab	
(Paz-Ares	et	al.,	2019)	to	chemotherapy	 in	first-line	compared	to	
chemotherapy alone. The latest National Comprehensive Cancer 
Network (NCCN) guidelines included these chemo-immunother-
apy regimens as a first-line option for ED SCLC patients (National 
Comprehensive Cancer Network®, 2019). Future studies capturing 
more recent years are needed to discover how these new treat-
ment options find their way in routine practice. Furthermore, due 
to the retrospective nature of the data collection, some data items 
were not captured, for example, site of metastases and the use of 
radiotherapy. Consequently, a statement about the impact of ra-
diotherapy and the localisation of metastases on treatment prog-
nosis was not possible.
Our findings are of interest when designing clinical trials for 
future drugs under study for ED SCLC. We showed that the num-
ber of patients who will be eligible for a second and/or third line 
of systemic therapy is limited in real-world. Furthermore, insight in 
treatment patterns is helpful to payers when considering the bud-
get impact (e.g. expected patient volume) of novel treatment options 
when they come available.
In conclusion, after first-line systemic treatment in ED SCLC the 
fraction of patients receiving subsequent lines of treatment is rap-
idly decreasing. This information is necessary as background for the 




complete the hospital pharmacy data.
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TA B L E  A 1   Baseline characteristics ED SCLC patients on start of first, second, or third line treatment
 
All treated patients in 
first-line
All treated patients in 
second-line
All treated patients 
in third-line
Patients, n (%) 568 231 68
Age	at	diagnosis,	median	(min-max) 66	(39–88) 64	(39–83) 62	(46–81)
Male, n (%) 311 (55) 118	(51) 35 (51)
Comorbidities	(CCI	≥	1),	n (%) 324 (57) 121 (52) 33 (49)
Missing 0 0 0
ECOG PS, n (%)
0–1 411 (72) 182	(79) 58	(85)
≥2 138	(24) 42	(18) 9 (13)
Missing 19 (3) 7 (3) 1 (1)
Abbreviations:	BSC,	best	supportive	care;	CCI,	Charlson	Comorbidity	Index;	CDE,	cyclophosphamide-doxorubicin-etoposide;	ECOG	PS,	Eastern	
Cooperative Oncology Group Performance Status.
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